Pulse Biosciences (PLSE) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Company overview and technology differentiation

• Developing next-generation nanosecond pulsed field ablation (nano PFA) for controlled, deep ablation with minimal collateral damage.

• Nano PFA enables larger electrodes and faster, more precise ablations compared to micro PFA.

• Holds over 150 global patents and leverages 20 years of scientific research.

• Extensive preclinical data library supports rapid product development.

• Strong leadership team with recent board expansion.

Clinical applications and product pipeline

• Initial dermatology application treated over 6,000 patients with strong safety record.

• Current focus on soft tissue ablation (benign thyroid nodules), surgical epicardial ablation, and endocardial catheter-based ablation for atrial fibrillation.

• Single console platform supports multiple applications with smart disposables.

• Emphasis on high-quality clinical data to drive rapid market adoption.

Clinical progress and regulatory strategy

• First-in-human studies for thyroid nodules completed in Italy and US; pivotal US study planned for first half of next year.

• Epicardial ablation tool received FDA breakthrough and TAP designation; first-in-human study underway in the Netherlands.

• Endocardial 360 catheter study expanded in Prague, with additional European centers joining.

• All products targeting specific regulatory pathways (PMA for cardiac tools) to enable aggressive market entry.